In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 2, 1999, Pages 179-192

  Candiani, Gianpaolo ^a   Abbondi, Monica ^a   Borgonovi, Monica ^a,b   Romanò, Gabriella ^a   Parenti, Franco ^a  

^a Biosearch Italia   (Italy)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DALBAVANCIN; GLYCOPEPTIDE; ORITAVANCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PENICILLIN RESISTANCE; RAT; SEPTICEMIA; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; RATS; SEPSIS; TEICOPLANIN; VANCOMYCIN;

EID: 0032802189     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.2.179     Document Type: Article

References (32)

1. Colley, E. W., McNicol, M. W. & Bracken, P. M. (1965). Methicillin-resistant staphylococci in a general hospital. Lancet 191, 595-7.
2. Edmond, M. B., Wenzel, R. P. & Pasculle, A. W. (1996). Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Annals of Internal Medicine 124, 329-34.
3. Saravolatz, D. L., Pohlod, D. J. & Arking, L. M. (1982). Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Annals of Internal Medicine 97, 325-9.
4. Schmitz, F. J. & Jones, M. E. (1997). Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? International Journal of Antimicrobial Agents 9, 1-19.
5. Pujol, M., Peña, C., Pallares, R., Ayats, J., Ariza, J. & Gudiol, F. (1994). Risk factors for nosocomial bacteraemia due to methicillin-resistant Staphylococcus aureus. European Journal of Clinical Microbiology and Infectious Diseases 13, 96-102.
6. Martin, M. A. (1994). Methicillin-resistant Staphylococcus aureus: the persistent resistant nosocomial pathogen. Current Clinical Topics in Infectious Diseases 14, 170-91.
7. Archer, G. L. & Climo, M. W. (1994). Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 38, 2231-7.
8. Kloos, W. E. & Bannerman, T. L. (1994). Update on clinical significance of coagulase-negative staphylococci. Clinical Microbiology Reviews 7, 117-40.
9. Oppenheim, B. A. (1998). The changing pattern of infection in neutropenic patients. Journal of Antimicrobial Chemotherapy 41, Suppl. D, 7-11.
10. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
11. Baquero, F., Martínez-Beltrán, J. & Loza, E. (1991). A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. Journal of Antimicrobial Chemotherapy 28, Suppl. C, 31-8.
12. Nava, J. M., Bella, F., Garau, J., Lite, J., Morera, M., Marti, C. et al. (1994). Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clinical Infectious Diseases 19, 884-90.
13. Brumfitt, W. & Hamilton-Miller, J. M. T. (1994). The challenge of methicillin-resistant Staphylococcus aureus. Drugs under Experimental and Clinical Research 20, 215-24.
14. Mulligan, M. E., Murray-Leisure, K. A., Ribner, B. S., Standiford, H. C., John, J. F., Korvick, J. A. et al.199?. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. American Journal of Medicine 94, 313-28.
15. Cooper, G. L. & Given, D. B. (1986). Vancomycin: a Comprehensive Review of 30 Years of Clinical Experience. Park Row Publishers, New York.
16. Williams, A. H. & Grüneberg, R. N. (1984). Teicoplanin. Journal of Antimicrobial Chemotherapy 14, 441-5.
17. Goldstein, F. W., Coutrot, A., Sieffer, A. & Acar, J. F. (1990). Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 34, 899-900.
18. Schwalbe, R. S., Stapleton, J. T. & Gilligan, P. H. (1987). Emergence of vancomycin resistance in coagulase-negative staphylococci. New England Journal of Medicine 316, 927-31.
19. Sieradzki, K., Villari, P. & Tomasz, A. (1998). Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrobial Agents and Chemotherapy 42, 100-7.
20. Veach, L. A., Pfaller, M. A., Barrett, M., Koontz, F. P. & Wenzel, R. P. (1990). Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. Journal of Clinical Microbiology 28, 2064-8.
21. Woodford, N., Johnson, A. P., Morrison, D. & Speller, D. C. (1995). Current perspectives on glycopeptide resistance. Clinical Microbiology Reviews 8, 585-615.
22. Campoli-Richards, D. M., Brogden, R. N. & Faulds, D. (1990). Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 40, 449-86. [erratum Drugs 41, 716].
23. De Lalla, F. & Tramarin, A. (1995). A risk-benefit assessment of teicoplanin in the treatment of infections. Drug Safety 13, 317-28.
24. Goldstein, B. P., Candiani, G. P., Arain, T. M., Romanò, G., Ciciliato, I., Berti, M. et al. (1995). Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrobial Agents and Chemotherapy 39, 1580-8.
25. Candiani, G. P., Abbondi, M., Borgonovi, M. & Williams, R. (1997). Experimental lobar pneumonia due to penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in immunocompetent and neutropenic rats: efficacy of penicillin and teicoplanin treatment. Journal of Antimicrobial Chemotherapy 39, 199-207.
26. Berti, M., Candiani, G., Borgonovi, M., Landini, P., Ripamonti, F., Scotti, R. et al. (1992). Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in-vitro and in experimental infections. Antimicrobial Agents and Chemotherapy 36, 446-52.
27. Finney, D. J. (1952). The Spearman-Kärber method. In Statistical Method in Biological Assay (Finney, D. J., Ed), pp. 524-30. Charles Griffin & Company Limited, London.
28. Godfrey, K. (1985). Statistics in practice: comparing the means of several groups. New England Journal of Medicine 313, 1450-6.
29. Peetermans, W. E., Hoogeterp, J. J., Hazekamp-Van Dokkum, A. M., van den Broek, P. & Mattie, H. (1990). Antistaphylococcal activities of teicoplanin and vancomycin in-vitro and in an experimental infection. Antimicrobial Agents and Chemotherapy 34, 1869-74.
30. 14C]teicoplanin in male rats after single Intravenous dose. Antimicrobial Agents and Chemotherapy 30, 733-8.
31. Borgonovi, M., Cavenaghi, L. A., Borghi, A., Galimberti, M., Kaltofen, P., Merati, R. et al. (1995). Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat. Antimicrobial Agents and Chemotherapy 39, 2176-82.
32. Kenny, M. T., Brackman, M. A. & Dulworth, J. K. (1995). In-vitro activity of the semisynthetic glycopeptide amide MDL 63,246. Antimicrobial Agents and Chemotherapy 39, 1589-90.